AR037771A1 - Moleculas pequenas para el tratamiento del crecimiento celular anormal - Google Patents
Moleculas pequenas para el tratamiento del crecimiento celular anormalInfo
- Publication number
- AR037771A1 AR037771A1 ARP020104778A ARP020104778A AR037771A1 AR 037771 A1 AR037771 A1 AR 037771A1 AR P020104778 A ARP020104778 A AR P020104778A AR P020104778 A ARP020104778 A AR P020104778A AR 037771 A1 AR037771 A1 AR 037771A1
- Authority
- AR
- Argentina
- Prior art keywords
- small molecules
- treatment
- cell growth
- abnormal cell
- erbb2
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
Moléculas pequenas que son útiles en el tratamiento del crecimiento celular anormal, tal como el cáncer, en mamíferos. Procedimiento de uso de tales moléculas pequenas en el tratamiento del crecimiento celular anormal en mamíferos, especialmente en seres humanos, y a composiciones farmacéuticas que contienen tales compuestos. Pequenas moléculas que son selectivas para el receptor erbB2 respecto al receptor erbB1, teniendo dicho inhibidor de erbB2 un intervalo de selectividades por erbB2 respecto a erbB1 entre 50-1500.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34109101P | 2001-12-12 | 2001-12-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR037771A1 true AR037771A1 (es) | 2004-12-01 |
Family
ID=23336198
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020104778A AR037771A1 (es) | 2001-12-12 | 2002-12-10 | Moleculas pequenas para el tratamiento del crecimiento celular anormal |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US20030171386A1 (es) |
| EP (1) | EP1465632A1 (es) |
| JP (1) | JP4181502B2 (es) |
| KR (1) | KR20040063948A (es) |
| CN (1) | CN1602195A (es) |
| AP (1) | AP2004003058A0 (es) |
| AR (1) | AR037771A1 (es) |
| AU (1) | AU2002339687A1 (es) |
| BR (1) | BR0214499A (es) |
| CA (1) | CA2469670A1 (es) |
| DO (1) | DOP2002000545A (es) |
| EA (1) | EA200400680A1 (es) |
| EC (1) | ECSP045146A (es) |
| GT (1) | GT200200273A (es) |
| HR (1) | HRP20040529A2 (es) |
| HU (1) | HUP0501069A2 (es) |
| IL (1) | IL161908A0 (es) |
| IS (1) | IS7233A (es) |
| MA (1) | MA27154A1 (es) |
| MX (1) | MXPA04004107A (es) |
| NO (1) | NO20042882L (es) |
| OA (1) | OA12734A (es) |
| PA (1) | PA8561301A1 (es) |
| PE (1) | PE20030760A1 (es) |
| PL (1) | PL373848A1 (es) |
| TN (1) | TNSN04111A1 (es) |
| TW (1) | TW200301121A (es) |
| WO (1) | WO2003049740A1 (es) |
| ZA (1) | ZA200404264B (es) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6924285B2 (en) | 2002-03-30 | 2005-08-02 | Boehringer Ingelheim Pharma Gmbh & Co. | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them |
| ES2400339T3 (es) | 2002-07-15 | 2013-04-09 | Symphony Evolution, Inc. | Compuestos, composiciones farmacéuticas de los mismos y su uso en el tratamiento del cáncer |
| BR0317433A (pt) * | 2002-12-18 | 2005-11-16 | Pfizer Prod Inc | Derivados bicìclicos para o tratamento do crescimento celular anormal |
| JP2006512355A (ja) * | 2002-12-19 | 2006-04-13 | ファイザー・プロダクツ・インク | Ｅ−２−メトキシ−ｎ−（３−｛４−［３−メチル−４−（６−メチルピリジン−３−イルオキシ）−フェニルアミノ］−キナゾリン−６−イル｝−アリル）−アセトアミドの複合体、それらの製造方法および使用 |
| BRPI0413745A (pt) * | 2003-08-18 | 2006-10-24 | Pfizer Prod Inc | horário mde dosagem para agentes anticancerìgenos erbb2 |
| EP2612853A1 (en) * | 2003-09-26 | 2013-07-10 | Exelixis Inc. | c-Met modulators and methods of use |
| CN1921864A (zh) * | 2003-12-24 | 2007-02-28 | 西奥斯公司 | 使用TGF－β抑制剂治疗神经胶质瘤 |
| UA85706C2 (en) * | 2004-05-06 | 2009-02-25 | Уорнер-Ламберт Компани Ллси | 4-phenylaminoquinazolin-6-yl amides |
| GB0417107D0 (en) * | 2004-07-30 | 2004-09-01 | Wellcome Trust The | Genes II |
| EP1896451A2 (en) * | 2005-06-03 | 2008-03-12 | Pfizer Products Incorporated | Bicyclic derivatives for the treatment of abnormal cell growth |
| EP1921070A1 (de) | 2006-11-10 | 2008-05-14 | Boehringer Ingelheim Pharma GmbH & Co. KG | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung |
| JPWO2008072634A1 (ja) | 2006-12-12 | 2010-04-02 | 武田薬品工業株式会社 | 縮合複素環化合物 |
| MX2009007610A (es) | 2007-02-06 | 2009-07-24 | Boehringer Ingelheim Int | Heterociclicos biciclicos, medicamentos que contienen estos compuestos, su utilizacion y procedimientos para su preparacion. |
| WO2009098061A1 (de) | 2008-02-07 | 2009-08-13 | Boehringer Ingelheim International Gmbh | Spirocyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
| TW200944528A (en) | 2008-03-12 | 2009-11-01 | Takeda Pharmaceutical | Fused heterocyclic compound |
| NZ589883A (en) | 2008-05-13 | 2012-06-29 | Astrazeneca Ab | Fumarate salt of 4- (3-chloro-2-fluoroanilino) -7-methoxy-6- { [1- (n-methylcarbamoylmethyl) piperidin- 4-yl] oxy} quinazoline |
| JP5539351B2 (ja) | 2008-08-08 | 2014-07-02 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | シクロヘキシルオキシ置換ヘテロ環、これらの化合物を含有する医薬、およびそれらを生成するための方法 |
| TWI447108B (zh) | 2009-01-16 | 2014-08-01 | Exelixis Inc | Ｎ－（４－｛〔６，７雙（甲氧基）喹啉－４－基〕氧基｝苯基）－ｎ’－（４－氟苯基）環丙烷－１，１－二甲醯胺之蘋果酸鹽及其結晶型 |
| UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
| US8993634B2 (en) | 2010-06-02 | 2015-03-31 | The Trustees Of The University Of Pennsylvania | Methods and use of compounds that bind to Her2/neu receptor complex |
| US9265739B2 (en) | 2010-06-02 | 2016-02-23 | The Trustees Of The University Of Pennsylvania | Methods and use of compounds that bind to HER2/neu receptor complex |
| US9526648B2 (en) | 2010-06-13 | 2016-12-27 | Synerz Medical, Inc. | Intragastric device for treating obesity |
| US10420665B2 (en) | 2010-06-13 | 2019-09-24 | W. L. Gore & Associates, Inc. | Intragastric device for treating obesity |
| US10010439B2 (en) | 2010-06-13 | 2018-07-03 | Synerz Medical, Inc. | Intragastric device for treating obesity |
| US8628554B2 (en) | 2010-06-13 | 2014-01-14 | Virender K. Sharma | Intragastric device for treating obesity |
| RU2614254C2 (ru) | 2011-08-31 | 2017-03-24 | Дженентек, Инк. | Диагностические маркеры |
| US9468681B2 (en) | 2013-03-01 | 2016-10-18 | California Institute Of Technology | Targeted nanoparticles |
| KR101589632B1 (ko) | 2014-06-03 | 2016-02-01 | 한국과학기술연구원 | 항암활성을 가지는 6-벤질옥시퀴나졸린-7-일유레아 유도체 |
| WO2017003668A1 (en) | 2015-07-01 | 2017-01-05 | California Institute Of Technology | Cationic mucic acid polymer-based delivery systems |
| US10779980B2 (en) | 2016-04-27 | 2020-09-22 | Synerz Medical, Inc. | Intragastric device for treating obesity |
| US20190381188A1 (en) | 2018-06-13 | 2019-12-19 | California Institute Of Technology | Nanoparticles For Crossing The Blood Brain Barrier And Methods Of Treatment Using The Same |
| JP2023512174A (ja) | 2020-02-03 | 2023-03-24 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ＨＥＲ２阻害薬としての［１，３］ジアジノ［５，４－ｄ］ピリミジン |
| JP2023512175A (ja) * | 2020-02-03 | 2023-03-24 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ＨＥＲ２阻害薬としての［１，３］ジアジノ［５，４－ｄ］ピリミジン |
| CN113429390B (zh) * | 2020-03-23 | 2022-04-15 | 苏州恩华生物医药科技有限公司 | 喹唑啉衍生物及其应用 |
| US11608343B2 (en) * | 2020-04-24 | 2023-03-21 | Boehringer Ingelheim International Gmbh | Substituted pyrimido[5,4-d]pyrimidines as HER2 inhibitors |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5721237A (en) * | 1991-05-10 | 1998-02-24 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties |
| US5679683A (en) * | 1994-01-25 | 1997-10-21 | Warner-Lambert Company | Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
| IL112249A (en) * | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
| GB9603095D0 (en) * | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| ZA986729B (en) * | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitors of tyrosine kinases |
| ZA986732B (en) * | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
| UA71945C2 (en) * | 1999-01-27 | 2005-01-17 | Pfizer Prod Inc | Substituted bicyclic derivatives being used as anticancer agents |
| JP3270834B2 (ja) * | 1999-01-27 | 2002-04-02 | ファイザー・プロダクツ・インク | 抗がん剤として有用なヘテロ芳香族二環式誘導体 |
| EP1192151B1 (en) * | 1999-07-09 | 2007-11-07 | Glaxo Group Limited | Anilinoquinazolines as protein tyrosine kinase inhibitors |
| AU778588B2 (en) * | 1999-10-19 | 2004-12-09 | Merck Sharp & Dohme Corp. | Tyrosine kinase inhibitors |
| EE200200710A (et) * | 2000-06-22 | 2004-06-15 | Pfizer Products Inc. | Asendatud bitsüklilised derivaadid ebanormaalse rakukasvu raviks |
| PL370858A1 (en) * | 2001-12-12 | 2005-05-30 | Pfizer Products Inc. | Salt forms of e-2-methoxy-n-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide and method of production |
-
2002
- 2002-11-04 HU HU0501069A patent/HUP0501069A2/hu unknown
- 2002-11-04 JP JP2003550789A patent/JP4181502B2/ja not_active Expired - Fee Related
- 2002-11-04 CN CNA028237293A patent/CN1602195A/zh active Pending
- 2002-11-04 BR BR0214499-9A patent/BR0214499A/pt not_active IP Right Cessation
- 2002-11-04 EA EA200400680A patent/EA200400680A1/ru unknown
- 2002-11-04 EP EP02777736A patent/EP1465632A1/en not_active Withdrawn
- 2002-11-04 MX MXPA04004107A patent/MXPA04004107A/es not_active Application Discontinuation
- 2002-11-04 AP APAP/P/2004/003058A patent/AP2004003058A0/en unknown
- 2002-11-04 KR KR10-2004-7009022A patent/KR20040063948A/ko not_active Application Discontinuation
- 2002-11-04 IL IL16190802A patent/IL161908A0/xx unknown
- 2002-11-04 CA CA002469670A patent/CA2469670A1/en not_active Abandoned
- 2002-11-04 AU AU2002339687A patent/AU2002339687A1/en not_active Abandoned
- 2002-11-04 PL PL02373848A patent/PL373848A1/xx not_active Application Discontinuation
- 2002-11-04 OA OA1200400160A patent/OA12734A/en unknown
- 2002-11-04 WO PCT/IB2002/004636 patent/WO2003049740A1/en active Application Filing
- 2002-12-10 TW TW091135662A patent/TW200301121A/zh unknown
- 2002-12-10 AR ARP020104778A patent/AR037771A1/es unknown
- 2002-12-10 PE PE2002001190A patent/PE20030760A1/es not_active Application Discontinuation
- 2002-12-10 DO DO2002000545A patent/DOP2002000545A/es unknown
- 2002-12-10 US US10/315,863 patent/US20030171386A1/en not_active Abandoned
- 2002-12-12 PA PA20028561301A patent/PA8561301A1/es unknown
- 2002-12-12 GT GT200200273A patent/GT200200273A/es unknown
-
2004
- 2004-04-26 IS IS7233A patent/IS7233A/is unknown
- 2004-05-31 ZA ZA200404264A patent/ZA200404264B/en unknown
- 2004-06-08 MA MA27731A patent/MA27154A1/fr unknown
- 2004-06-09 HR HR20040529A patent/HRP20040529A2/hr not_active Application Discontinuation
- 2004-06-10 EC EC2004005146A patent/ECSP045146A/es unknown
- 2004-06-11 TN TNP2004000111A patent/TNSN04111A1/fr unknown
- 2004-07-07 NO NO20042882A patent/NO20042882L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1465632A1 (en) | 2004-10-13 |
| PA8561301A1 (es) | 2003-12-30 |
| JP2005527486A (ja) | 2005-09-15 |
| BR0214499A (pt) | 2005-05-10 |
| IL161908A0 (en) | 2005-11-20 |
| CN1602195A (zh) | 2005-03-30 |
| PE20030760A1 (es) | 2003-09-05 |
| GT200200273A (es) | 2003-10-03 |
| OA12734A (en) | 2006-06-28 |
| HRP20040529A2 (en) | 2004-10-31 |
| ZA200404264B (en) | 2005-08-31 |
| US20030171386A1 (en) | 2003-09-11 |
| ECSP045146A (es) | 2004-07-23 |
| EA200400680A1 (ru) | 2005-06-30 |
| MA27154A1 (fr) | 2005-01-03 |
| DOP2002000545A (es) | 2003-06-16 |
| NO20042882L (no) | 2004-07-07 |
| AU2002339687A1 (en) | 2003-06-23 |
| IS7233A (is) | 2004-04-26 |
| HUP0501069A2 (en) | 2006-06-28 |
| PL373848A1 (en) | 2005-09-19 |
| TW200301121A (en) | 2003-07-01 |
| CA2469670A1 (en) | 2003-06-19 |
| WO2003049740A1 (en) | 2003-06-19 |
| AP2004003058A0 (en) | 2004-06-30 |
| KR20040063948A (ko) | 2004-07-14 |
| MXPA04004107A (es) | 2004-07-23 |
| JP4181502B2 (ja) | 2008-11-19 |
| TNSN04111A1 (fr) | 2006-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR037771A1 (es) | Moleculas pequenas para el tratamiento del crecimiento celular anormal | |
| PA8468401A1 (es) | Compuestos para el tratamiento de la isquemia | |
| PA8680701A1 (es) | Derivados de oxindol | |
| ECSP055582A (es) | Derivados de benzotiazol que tienen actividad agonista de beta-2-adrenorreceptor | |
| ECSP066406A (es) | Derivados de pirimidina para el tratamiento del crecimiento celular anormal | |
| ECSP045407A (es) | Benzazoles sustituidos y el uso del mismo como inhibidores de quinasa raf | |
| ECSP003682A (es) | Compuestos para el tratamiento de la isquemia | |
| UY29086A1 (es) | Nuevas composiciones farmacéuticas para el tratamiento de trastornos hiperproliferativos. | |
| PA8643201A1 (es) | Compuestos de aminoheteroarilo sustituidos con pirazol como inhibidores de proteina quinasa | |
| GT200600517A (es) | Derivados de pirimidina para el tratamiento del crecimiento celular anormal | |
| ECSP109957A (es) | Derivados de pirimidinil-piridazinona. | |
| CO4560552A1 (es) | Antagonistas de receptores de taquicininas no peptidicos | |
| BRPI0514474A (pt) | multiparticulados | |
| UY27732A1 (es) | Uso de análogos del benzimidazol en el tratamiento de la proliferación celular. | |
| NI200800060A (es) | Bencimidazoles sustituidos como inhibidores de cinasa. | |
| UY28731A1 (es) | Compuestos quimicos | |
| AR049915A1 (es) | Compuestos con contenido de boro y metodos de uso de los mismos | |
| CL2009000448A1 (es) | Compuestos derivados de 3-sulfonilamino-n-(1h-pirazolo-[3,4-b]piridin-5il)benzamida; procesos de preparacion; compuestos intermediarios; composicion farmaceutica; y uso para el tratamiento del cancer, tal como sarcoma, carcinoma, adenoma, entre otros. | |
| UY27894A1 (es) | Derivados de cinamida. | |
| UY29685A1 (es) | Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen. | |
| CL2008000202A1 (es) | Compuestos derivados de n-aril-acetamida, antagonista trpv1;composicion farmaceutica que los comprende, utiles en el tratamiento del dolor. | |
| UY27452A1 (es) | Compuestos de benzimidazol sustituido y su uso para el tratamiento del cancer | |
| UY29109A1 (es) | Derivados de alquiliden-tetrahidronaftaleno, procedimiento para su preparacion y su uso como antiinflamatorios | |
| SV2008002856A (es) | 2-amino-7, 8-dihidro-6h-pirido [4,3-d] pirimidina-5-onas | |
| UY29925A1 (es) | Derivados de 9-cloro-15-desoxiprostaglandina, procesos para su preparación y su uso como medicamento. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |